Investigations of urethral sphincter activity in mice with bladder hyperalgesia before and after drug administration of gabapentin. by Yeh, Jih-Chao et al.
UC Irvine
UC Irvine Previously Published Works
Title
Investigations of urethral sphincter activity in mice with bladder hyperalgesia before and 
after drug administration of gabapentin.
Permalink
https://escholarship.org/uc/item/7jg4w3d2
Journal
International urology and nephrology, 51(1)
ISSN
0301-1623
Authors
Yeh, Jih-Chao
Do, Rebecca
Choi, Hanul
et al.
Publication Date
2019
DOI
10.1007/s11255-018-2021-8
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Investigations of urethral sphincter activity in mice with bladder 
hyperalgesia before and after drug administration of gabapentin
Jih-Chao Yeh, PhD1, Rebecca Do, BS2, Hanul Choi, BS2, Ching-Ting Lin, BS3, Jia-Jin Chen, 
PhD3, Xiaolin Zi, PhD2, Huiyi H. Chang, PhD2,4,*, and Gamal Ghoniem, MD2,*
1Urology at University of Southern California, Los Angeles, California, USA
2Urology at University of California Irvine, Irvine, California, USA
3Biomedical Engineering at National Cheng Kung University, Tainan, TAIWAN
4Reeve-Irvine Research Center at University of California Irvine, California, USA
Abstract
Purpose: This study investigated the effect of gabapentin on lower urinary tract dysfunction 
focusing on urethral activities and cystitis-induced visceral hyperalgesia in a mouse model of 
painful bladder syndrome/ interstitial cystitis (PBS/IC). The electromyography of urethral 
sphincter was difficult to obtain, but contained useful information to examine the drug effect in 
mice.
Methods: Female C57BL/6J mice were intraperitoneally (ip) dosed with either saline or 200 
mg/kg of cyclophosphamide (CYP) 48 hours before experimental evaluation. Cystitis mice were 
treated with administration of Gabapentin (25 or 50 mg/kg, ip). Bladder and external urethral 
sphincter (EUS) functions were obtained and analyzed during continuous bladder infusion. The 
visceral pain-related visceromotor reflex (VMR) was recorded in response to isotonic bladder 
distension.
Results: Cystitis mice showed shorter inter-contraction intervals and increased occurrence of 
non-voiding contractions during bladder infusion, with increased VMR during IBD, indicating 
cystitis-induced bladder hyperalgesia. Gabapentin (50 mg/kg) suppressed effects of CYP on 
cystometry, but not on EUS activity, during bladder infusion. The effect on urodynamic recordings 
lasted 4 hours. VMR was significantly reduced by gabapentin.
Conclusions: The present study showed that CYP-induced cystitis in mice is a model of visceral 
hyperalgesia affecting detrusor contractions, not urethral activations. The technique of using EUS 
electromyography to evaluate the drug effects on urethral activities is novel and useful for future 
investigations. Gabapentin can be as a potential treatment for detrusor overactivity and PBS/IC.
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INTRODUCTION
Painful bladder syndrome/ interstitial cystitis (PBS/IC) is a prevalent disease affecting over a 
million people in the United States. The disease is associated with increased urinary 
frequency, urgency, and pain originating from the urinary bladder [1]. Although medical 
treatments and procedures, such as bladder instillation, hydrodistension, and oral 
pharmaceutical drugs are available for PBS/IC, many of these treatments are effective only 
in a percentage of patients [1,2].
Gabapentin is clinically used to treat PBS/IC. It is an anti-epileptic medication that can bind 
to the α−2-delta subunit of voltage-dependent calcium channels leading to a reduction of the 
influx of calcium into neurons throughout central nervous system [3]. As a result, it shows 
the beneficial effect on chronic pain by inhibiting the C afferent activity [4-7]. A combined 
treatment in PBS/IC patients for four weeks by giving a low dose of gabapentin (300 mg) 
with amitriptyline for overactive bladder symptoms significantly reduces urinary urgency, 
frequency, and bladder pain [8]. More studies indicate that the neurogenic detrusor 
overactivity can be suppressed by gabapentin in the children with the repair of spinal bifida 
and refractory overactive bladder [4,6]. However, the drug effect of gabapentin on voiding 
function, especially the urethral activities, in the type of cystitis-induced bladder 
hyperalgesia is not thoroughly understood.
Animal studies have been suggested that cyclophosphamide (CYP) induce the detrusor 
overactivity and bladder hyperalgesia, similar to the PBS/IC [9-12], There is no evidence 
showing the urethral function associated with the detrusor contractions in the mouse model 
of CYP-induced cystitis. The electromyography of urethral sphincter was difficult to obtain, 
but contained useful information to examine the drug effect in mice. This study is the first 
few of studies to investigate the drug effect of gabapentin on the urethral activations during 
voiding. Besides, the visceromotor reflex (VMR) is used as an indicator of the level of 
visceral pain triggered by bladder distension because it is known for quantifying the level of 
nociception in CYP-induced cystitis rodent models [9,13,14]. Therefore, we investigated the 
effects of gabapentin on cystometry, urethral activation and visceral-pain related VMR in a 
mouse model of cystitis-induced hyperalgesia.
MATERIALS AND METHODS
Animal model
All experiments were approved and carried out in accordance with National Institutes of 
Health guidelines, and approved by the Institutional Animal Care and Use Committees at 
University of Southern California and University of California Irvine, CA, USA. Twenty 
female C57BL/6J mice (aged 4-6 weeks, 20-25g) were used in the study. The mice received 
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either intraperitoneally (ip) administered 0.2 mL saline (controls, n=10) or CYP (200 mg/kg, 
n=10), 48 hours prior to urodynamic recordings.
Surgical preparations for urodynamic recordings and VMR
Urethane (1.5 g/kg) were subcutaneously given to the animals 1 hour before surgical 
preparation. The pubic symphysis was removed to expose the urethra and external urethral 
sphincter (EUS). Two fine, insulated silver wire electrodes (0.05 mm in diameter, A-M 
system, WA) with 2-mm exposed tip were bilaterally inserted into the EUS, approximately 
2-3 mm from the bladder neck, to record the electromyographic (EMG) activity of EUS 
[15-17]. Additional two wire electrodes with 2-mm exposed tips were embedded into the 
external oblique muscle to obtain VMR. Finally, a polyethylene-50 catheter (Instech 
Laboratories, MA) was inserted into the bladder dome and secured with a cotton thread. 
This catheter was then connected to an infusion pump (Kent Scientific, CT) and a pressure 
sensor (Biopac Systems Inc., CA) via a 3-way connector to infuse the bladder and to obtain 
cystometry. The bladder was infused with 0.9% normal saline (0.03 mL/min). The 
cystometry, EUS EMG activity, and VMR were recorded and analyzed by using a data 
acquisition system (MP150, Biopac Systems Inc., CA) [17].
VMR during isotonic bladder distension (IBD)
After obtaining baseline of urodynamic recordings, the urethra outlet was occluded by the 
5-0 silk suture. VMR was then measured during IBD (10 to 50 cmH2O) by distending the 
bladder to a constant pressure through rapidly changing the height of a saline-filled 
reservoir. The bladder achieved to each constant pressure within 1 sec and sustained for 120 
seconds. Following each level of the desired intravesical pressure (IVP), the bladder was 
emptied and allowed to rest for 120 seconds.
Gabapentin administration
Gabapentin (Sigma-Aldrich, MO) was dissolved in 0.9% normal saline, and 
intraperitoneally administered to the control and cystitis mice. After the acquisition of 
baseline urodynamic recordings and VMR during IBD, control and cystitis mice were 
randomly assigned into following groups: control mice with (1) 25 mg/kg (n=5) and (2) 50 
mg/kg (n=5), cystitis mice with (3) 25 mg/kg (n=5) and (4) 50 mg/kg (n=5). After drug 
administrations, both urodynamic evaluation and VMR during IBD were obtained again 
within 30 minutes. Further drug effects on urodynamic recordings were also examined at 1 
and 4 hours after the initial administration at each dose.
Statistical Analysis
Three consecutive voiding cycles were measured at the second hour after the beginning of 
the urodynamic recordings. The outcome measurements were analyzed including the actual 
maximum IVP, resting pressure after voiding (RP), inter-contraction intervals (ICI), bladder 
capacity, and non-voiding contractions (NVCs). The bladder capacity was calculated by the 
latency of the first void (minute) × infusion rate (ml/min). The EUS EMG activity was also 
analyzed including the maximum amplitude, duration, and area under the curve (AUC) [17]. 
VMR AUC measured at the 120-seconds period during IBD.
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The non-parametric Mann-Whitney test were applied to determine differences in the 
measurements of urodynamic recordings between the control and cystitis groups without the 
drug. The non-parametric Wilcoxon matched-paired test were used among the control and 
cystitis groups before and after drug administration. Data was presented as both mean and 
standard error (mean ± SE). A value of p<0.05 indicates significant differences. GraphPad 
Prism 6 (GraphPad Software, CA) was applied for statistical analysis and graph 
demonstrations.
RESULTS
Urodynamic recordings, including cystometry and EUS EMG activity, and VMR during 
IBD, were investigated in control (n=10) and CYP-induced cystitis (n=10) mice, as well as 
following administration of gabapentin at either 25 or 50 mg/kg in these two groups.
Urodynamic recordings before and after drug administration in control mice
The control mice (n=10) underwent the urodynamic recordings (Fig. 1A) and VMR during 
IBD to obtain the baseline before drug administration. Then, the control mice received the 
administration of gabapentin (25 or 50 mg/kg, n=5 at each dose). The urodynamic 
recordings were obtained at 1 hour and 4 hours after drug administration (Table 1). The 
urodynamic recordings from the control mice were not significantly affected by gabapentin 
(Table 1).
Urodynamic recordings without drug in cystitis mice
The cystitis mice (n=10) significantly showed increased maximum IVP and shorter ICI 
when compared to the controls (unpaired t-test, n=10, p=0.04 and 0.02, respectively, Table 
1). The cystitis mice also showed the smaller bladder capacity compared to controls (p=0.03, 
Table 1). RP was not significantly increased when compared to controls (p=0.21, Table 1). 
The numbers of NVCs were also significantly increased in the cystitis mice (p=0.001, Table 
1; Fig. 1B). The maximum amplitude, AUC, and duration of EUS-EMG activity did not 
show any significant differences in the cystitis mice (p=0.87, 0.25, and 0.96, respectively, 
Table 1).
Urodynamic recordings after administration of gabapentin in cystitis mice
Gabapentin was given to the cystitis mice (n=10) after baseline urodynamic recordings were 
recorded. One hour after administration of gabapentin (25 and 50 mg/kg, n=5 at each dose), 
the maximum IVP was significantly decreased (Table 1). NVCs were significantly 
suppressed by gabapentin (Table 1, Fig. 1). At 4 hours following administration of 
gabapentin (25 and 50 mg/kg, Figs. 1C-D), the ICI was significantly prolonged as well as 
the NVCs was significantly reduced (Table 1) in the cystitis mice. However, the EUS EMG 
did not significantly change after administration of gabapentin in both doses (Table 1).
VMR during IBD
The control mice (n=10) showed the mild responses of VMR induced by the bladder 
distension at each IVP level. Administration of gabapentin (25 or 50 mg/kg, n=5 in each 
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dose) did not change the VMR at 10, 20, and 30 cmH2O in these control mice (Figure 4). 
The higher dose (50 mg/kg) significantly reduced VMR AUC at 40 and 50 cmH2O.
CYP-induced cystitis resulted in visceral nociception as evidenced by a significant increase 
of VMR AUC during IBD when the bladder pressure was increased from 10 to 50 cmH2O 
(Fig. 2). The effects of gabapentin (25 or 50 mg/kg, n=5 in each dose) on VMR were 
evaluated one hour following drug administration. The lower dose (25 mg/kg) did not 
change VMR AUC. However, the higher dose (50 mg/kg) significantly reduced VMR AUC 
at 20 cmH2O and higher IVP levels during IBD.
DISCUSSION
This study investigated the voiding function and visceral-nociception in the mouse model of 
acute CYP-induced cystitis. The present study demonstrated that cystitis resulted in detrusor 
overactivity as evidenced by increased voiding frequency and non-voiding contractions. The 
EUS EMG activity associated with voiding contractions in mice was also reported. 
Gabapentin (50 mg/kg, ip) significantly reduces detrusor overactivity and ameliorates the 
visceral nociception in the cystitis mice.
Effects of gabapentin on urodynamic and VMR in control mice
We first evaluated the effect of gabapentin on the urodynamic recordings and VMR during 
IBD in control mice. Surprisingly, gabapentin did not significantly change the urodynamic 
outcomes compared to the baseline before treatment. It is also believed that gabapentin 
reduces the pain sensation and bladder hyperalgesia by suppressing the C fibers 
hypersensitivity [4,5]. After nerve lesions or repeated stimulation, C fibers become 
abnormally sensitive and cause pathological neuronal responses to a noxious stimulus. Since 
the control mice were neurologically intact, the C fibers remain the normal function and 
sensitivity. Therefore, gabapentin did not affect the functional assessments. However, when 
the bladder was distended over the maximum IVP (28 cmH2O, Table 1) in control mice at 
40 and 50 cmH2O, the higher dose of gabapentin (50 mg/kg) significantly reduced VMR 
AUC. It may be resulted from the C-fiber hyper-sensitivity due to the over-distension of the 
bladder. Thus, gabapentin showed the suppression on VMR at higher IVP levels in control 
mice.
Effects of CYP on cystometry and urethral activities
In the present study, the cystitis mice showed significantly decreased ICI as well as 
increased NVCs that indicating detrusor overactivity. These results point to C-fibers being 
activated and sensitized by CYP-induced inflammation [13]. Maximum IVP significantly 
increased in cystitis mice compared to controls while the RP remained the same. The 
increase of IVP indicated that the voiding-associated abdominal wall contraction produced 
an increment of intra-abdominal pressure which promoted the total bladder pressure against 
resistance to drive urine flow [18]. Thus, the increase of abdominal wall contractions 
resulted in the increment of the abdominal wall EMG activity, and led to the increase of 
VMR.
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The EUS EMG activity associated with bladder contraction was first examined in the mice 
with CYP-induced cystitis. Surprisingly, the EUS EMG activity during the expulsed duration 
was not altered by cystitis. Although the epithelium of the bladder and urethra may be 
damaged as reported [14], the somatic efferent pathway may not be directly affected by 
CYP-induced inflammation. A study demonstrated that chronic low-dose administration of 
CYP in male mice caused detrusor overactivity, increased urinary frequency, and referred 
bladder hyperalgesia without impairment of physiological state and overt damage of bladder 
tissue [13]. This may explain why the EUS EMG activity remained the same in the cystitis 
mice. Furthermore, only a minority of the mice exhibit bursting-like EUS activity during 
voiding [15]. Unlikely, the rats commonly exhibit EUS bursting, which is essential for 
efficient voiding [19,20], The CYP-induced cystitis rats show stronger active periods but 
shorter silent periods of EUS bursting indicating the decreased urethral relaxation during 
voiding. The cystitis mice in the present study may not exhibit EUS bursting, and not able to 
show the significant changes of EUS activity before and after drug administrations.
Effects of gabapentin on detrusor overactivity and visceral pain-related VMR in cystitis 
mice
The drug effect of gabapentin on bladder function and CYP-induced bladder hyperalgesia 
was examined. The dose of 50 mg/kg significantly prolonged the ICI and reduced NVCs 
during bladder infusion indicating the improvements of urgency and voiding efficiency. The 
effect was maintained for at least 4 hours. In the present study, VMR during IBD is a well-
established method to evaluate the visceral hyperalgesia, and is directly related to the 
voiding function. 50 mg/kg of gabapentin in cystitis mice, but not in control mice, reduced 
VMR AUC at the lower IVP levels showing that the cystitis mice had hyper-sensitivity in 
response to bladder distension below voiding threshold. In our experimental settings, the 
dose of 50 mg/kg achieved the optimal condition of a significant reduction of detrusor 
overactivity and amelioration of visceral hyperalgesia.
CONCLUSIONS
Urinary urgency, frequency, discomfort and/or bladder pain are primary symptoms in 
PBS/IC patients. The present study is limited to the mouse model whereas the effects of 
gabapentin on neuropathic pain and PBS/IC in the humans are examined [1,2,8]. The 
strengths of this study using the mouse model of cystitis-induced hyperalgesia provide the 
important information inclusive of urethral investigation and the effect of gabapentin on 
treating PBS/IC and detrusor overactivity that are not thoroughly studied in animal models 
and humans. The techniques of using EUS EMG to examine the urethral activities were 
overcome to provide the useful information before and after drug administration. The 
present study has demonstrated that gabapentin (50 mg/kg) ameliorated detrusor overactivity 
and visceral pain-related VMR, but not urethral activation, caused by cystitis-induced 
hyperalgesia. The dosages of gabapentin need to be considered extensively in order to 
maintain the efficient voiding during treatments. Future studies will have to investigate 
effects of long term treatment with gabapentin on detrusor overactivity and bladder 
hyperalgesia in the chronic cystitis models. These long-term studies will have beneficial 
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information, including the improvement of detrusor overactivity and voiding function along 
with the pain relief, to the study designs of clinical/translational studies in humans.
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Fig. 1: 
Representative examples of urodynamic recordings in the control mouse (A) and cystitis 
mice before (B) and after drug administrations (C-D). In this cystitis mouse, the voiding and 
non-voiding contractions were more frequent during saline infusion. Urodynamic recordings 
obtained 4 hours after administrations of gabapentin (ip) of 25 mg/kg (C, cystitis+RX_25) 
and 50 mg/kg (D, cystitis+RX_50). Asterisks indicate the non-voiding contractions.
Yeh et al. Page 9
Int Urol Nephrol. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2: 
The effect of gabapentin on VMR during IBD. The bladder was distended by saline from 10 
to 50 cmH2O. In control mice, 25 mg/kg of gabapentin (control+Rx_25) did not suppress 
VMR AUC at any IVP levels. 50 mg/kg of gabapentin (control+Rx_50) significantly 
suppressed VMR AUC when the IVP at 40 and 50 cmH2O in control mice. The cystitis mice 
showed a significant increase of VMR AUC at each IVP level compared to controls. 25 
mg/kg of gabapentin (cystitis+Rx_25) did not suppress VMR AUC. However, 50 mg/kg of 
gabapentin (cystitis+Rx_50) significantly suppressed VMR AUC when the IVP was higher 
than 20 cmH2O. + p<0.05 indicated statistical significance in the group of control+Rx_50 
compared to the control mice without drug. # p<0.05 indicated statistical significance 
between the controls and cystitis mice. * p<0.05 and ** p<0.01 indicated statistical 
significance in the group of cystitis+Rx_50 compared to the cystitis mice without drug.
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